First-In-Human Study of Apramycin

NCT ID: NCT04105205

Last Updated: 2021-02-23

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 40 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-09-25
• Study Completion Date: 2020-10-16

Brief Summary

This is a first-in-human study to assess the safety, tolerability and pharmacokinetics of escalating single doses of apramycin. This trial will be conducted as a single ascending dose trial in up to 5 sequential dose cohorts (group-comparison). Each cohort will consist of 8 healthy subjects, 6 will receive apramycin and 2 placebo.

Conditions

Healthy Volunteers

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: QUADRUPLE

Study Groups

Apramycin injection in escalating doses

Apramycin, solution for infusion.

Group Type: EXPERIMENTAL

Apramycin injection

Intervention Type: DRUG

30-min infusion

Placebo

Physiological saline, solution for infusion.

Group Type: PLACEBO_COMPARATOR

Placebo injection

Intervention Type: DRUG

30-min infusion

Interventions

Apramycin injection

30-min infusion

Intervention Type: DRUG

Placebo injection

30-min infusion

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Healthy male and female subjects of non-childbearing potential, 18-45 years of age (both inclusive), body mass index 18.0 - 29.9 kg/m2 (inclusive) and body weight from 50 to 100 kg (inclusive).
• Glomerular filtration rate (GFR) ≥ 90 mL/min /1.73 m2.
• Subjects with systemic hearing, with air conduction thresholds no worse than 20 decibels (dB) hearing loss for the frequencies 0.5-1-2-4-6-8 kilohertz (kHz) bilaterally and, no threshold asymmetry ≥ 20 dB at any frequency, normal (reproducibility 70% or better) transient evoked otoacoustic emissions (TEOAE).
• From the signing of the informed consent until the last follow-up visit, subjects must be willing to avoid exposure to loud noise and Subjects must be willing to avoid excessive physical exercise within 48 h prior to dosing.
• Normal blood pressure and pulse rate, ECG recording without clinically significant abnormalities.
• Thyroid-stimulating hormone, free triiodothyronine and free thyroxine within the reference ranges.
• Having had no febrile or infectious illness for at least 7 days prior to the first administration of the Investigational medicinal product (IMP) of the study.
• Normal microscopic findings in the ears, normal tympanic membrane mobility and stapedial reflex present.

Exclusion Criteria

• Vegetarian or vegan.
• Demonstrating excess in xanthine consumption.
• More than low-risk alcohol consumption (men: ≥24 g of pure alcohol regularly per day; women: ≥12 g of pure alcohol regularly per day).
• Any history of alcohol or drug abuse or a positive urine drug screen test. Positive alcohol breath test.
• Consumption of xanthine-containing food or beverages within 48 h before dosing.
• Smokers smoking more than 10 cigarettes or equivalent per day.
• Exposure to loud noise within 3 days prior to drug administration.
• Taking any medication on a regular basis, with the exception of solitary doses of up to 1000 mg paracetamol.
• Use of any investigational drug product within 30 days or 5 half-lives before screening.
• Use of aminoglycosides or other antibiotics within 3 months prior to screening.
• Use of neuromuscular blocking agents within 1 week or 5 half-lives prior to screening.
• Use of potentially nephrotoxic medication 2 weeks prior to the drug administration.
• Any history of drug hypersensitivity, asthma, urticaria or other severe allergic diathesis as well as hay fever with ongoing symptoms.
• Any history of hypersensitivity to aminoglycosides.
• Any history or signs of acute, chronic or recurrent metabolic, renal, hepatic, pulmonary, gastrointestinal, neurological, neuromuscular disorders, endocrinological, immunological, psychiatric or cardiovascular disease, myopathies, and bleeding tendency.
• Problems with hearing and/or balance.
• Previous injury or surgery to the middle or inner ears, family history of hearing loss before the age of 60.
• Genetic predisposition to aminoglycoside-driven ototoxicity.
• Laboratory values outside the reference range that are of clinical relevance.
• Positive test for HIV antibodies, hepatitis B-virus surface antigen, or anti-hepatitis C-virus antibodies.
• Blood or plasma donation of 500 mL within 3 months or more than 100 mL within 30 days before signing an informed consent to this trial.
• Judged by the investigator to have occupational noise exposure of high risk during the trial.
• Positive test for SARS-CoV-2.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 45 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Innovative Medicines Initiative

OTHER

Sponsor Role: collaborator

Juvabis AG

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Armin Schultz, Dr.med.

Role: PRINCIPAL_INVESTIGATOR

CRS Clinical Research Services Mannheim GmbH

Locations

CRS Clinical Research Services Mannheim GmbH

Mannheim, , Germany

Countries

Germany

References

Roch M, Sierra R, Sands K, Martins WMBS, Schrenzel J, Walsh TR, Gales AC, Andrey DO. Vertical and horizontal dissemination of an IncC plasmid harbouring rmtB 16S rRNA methylase gene, conferring resistance to plazomicin, among invasive ST258 and ST16 KPC-producing Klebsiella pneumoniae. J Glob Antimicrob Resist. 2021 Mar;24:183-189. doi: 10.1016/j.jgar.2020.12.006. Epub 2020 Dec 26.

Reference Type: DERIVED

PMID: 33373732 (View on PubMed)

Other Identifiers

JUV18-01

Identifier Type: -

Identifier Source: org_study_id